publication date: Feb. 21, 2014
NCI has launched a pilot study to assess whether assigning cancer patients treatment based on the genetic characteristics of their disease can improve outcomes for patients with advanced metastatic solid tumors.
The Molecular Profiling based Assignment of Cancer Therapeutics, or M-PACT, trial is one of the first to use a randomized trial design to assign treatment based on specific mutations.
|NCI Clinical Trials Enrollment Drops to 17,500|
Enrollment in NCI-sponsored National Clinical Trials Network clinical trials will drop to about 17,500 this fiscal year, the network groups have been told by NCI officials.
This enrollment figure includes 3,600 pediatric patients, so the total adult enrollment will add up to about 14,000, insiders at cooperative groups say.
|GAO: FDA Data on Drug Shortages Inadequate|
FDA needs to improve its access to data if it is to manage drug shortages more effectively, the Government Accountability Office concluded.
The FDA’s management of drug shortage data is “inconsistent with federal internal control standards,” the GAO report states.
|Duke’s Dzau Named IOM President|
Victor Dzau, chancellor of health affairs at Duke University and president and CEO of the Duke University Health System, was named president of the Institute of Medicine.
Dzau will succeed current IOM president Harvey Fineberg effective July 1.
NCI’s John Czajkowski to take executive dean position at Harvard Medical School
Issam Markhoul named distinguished chair for hematology and oncology at University of Arkansas for Medical Sciences
Margaret Dimond named president of Karmanos Cancer Hospital
North Shore-LIJ Cancer Institute opens $47 million radiation facility
Duke-NUS Graduate Medical School Singapore partners with ImaginAb Inc.
St. Jude Thanks and Giving campaign rasies over $97 million
Roswell Park Cancer Institute to collaborate with GenomOncology
Roche Servicios S.A. and Cancer Genetics Inc. enter agreement
Novartis acquires CoStim Pharmaceuticals Inc.